Traders should monitor whether Mayo Clinic exercises its option to purchase the additional shares, which would provide SANA with another $25 million in funding. The partnership with Mayo Clinic for diabetes therapies could lead to future value creation, but investors should track the progress of these development programs.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $3.48entry
- T+1 · 7mo ago −1.15%α −1.92% · $3.44
- T+5 · 7mo ago +6.32%α +4.93% · $3.70
- T+20 · 6mo ago +2.30%α −4.00% · $3.56
- T+60 · 4mo ago +12.93%α +4.41% · $3.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sana Biotechnology entered into a stock purchase agreement with Mayo Clinic, selling 7.5 million shares for $25 million upfront, with an option for Mayo Clinic to purchase an additional 7.5 million shares for another $25 million. The proceeds will be used for developing diabetes therapies, and Mayo Clinic agreed to a six-month lock-up period.
Key Facts
- Sana Biotechnology sold 7,507,507 shares to Mayo Clinic for $24.999 million at $3.33 per share
- Mayo Clinic has the option to purchase an additional 7,507,507 shares for $24.999 million
- Proceeds will be used for developing products including SC451 and genetically modified stem-cell derived islet cell products
- Mayo Clinic agreed to a lock-up period of six months from the initial closing
- Sana's cash position of $138.4 million as of December 31, 2025, plus the anticipated $24.9 million from this transaction, is expected to fund operations into 2027
Financial Impact
Immediate $24.999 million in gross proceeds from the initial share sale, with potential for an additional $24.999 million if Mayo Clinic exercises its option
Risk Factors
- Dilution from the potential additional share issuance
- Dependence on successful development of diabetes therapies
- Mayo Clinic may choose not to exercise its option for additional shares
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152868 |
| Document: sana-20260410.htm | 0001193125-26-152868 |
| Document: sana-ex5_1.htm | 0001193125-26-152868 |
| Document: 0001193125-26-152868-index-headers.html | 0001193125-26-152868 |
| Document: 0001193125-26-152868-index.html | 0001193125-26-152868 |
| Document: 0001193125-26-152868.txt | 0001193125-26-152868 |
Track record
12 reports on SANA
2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 13, 202631w ago 8-K Bullish 6/10 Viewing Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
- Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers